Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Prabowo says DEFA can unlock $2 trillion ASEAN digital economy

    November 18, 2026

    Puravankara launches Purva Cityspire in Kochi with ₹2,000 crore GDV

    November 18, 2026

    LG Channels Expands Free Channel Offering in the UAE with Rakuten TV, Stingray and Red Bull TV

    November 18, 2026
    Facebook X (Twitter) Instagram
    UAE IndependentUAE Independent
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • More
      • Sports
      • Technology
      • Travel
    UAE IndependentUAE Independent
    Home » Cambridge Isotope Laboratories (CIL) Shows Long-Term Commitment to Xenia, Ohio, Facility With New Land Purchase
    ACCESS Newswire

    Cambridge Isotope Laboratories (CIL) Shows Long-Term Commitment to Xenia, Ohio, Facility With New Land Purchase

    April 25, 2024
    Facebook Twitter Pinterest LinkedIn Tumblr Email

    TEWKSBURY, MA / ACCESSWIRE / April 25, 2024 / Cambridge Isotope Laboratories, Inc. (CIL) has acquired an additional 14.8 acres of land at its Cambridge Isotope Separations (CIS) Xenia, Ohio location. Mike Steiger, Vice President of Engineering and Project Execution for CIL, stated that the new land purchase will ensure easier access to utilities for future expansion.

    Cambridge Isotope Separations
    Cambridge Isotope Separations

    This newly acquired land is situated to the west of the 20 acres purchased in 2017, which is currently the site of the North Star expansion project. This recently completed project will greatly increase 13C production and is in the startup phase. North Star is the largest 13C separation facility ever built in the world and will significantly increase CIL’s capacity ensuring customer reliability for this stable isotope.

    The land acquired provides the business flexibility to expand in the future as the demand continues to grow worldwide in all applications. “This investment shows CIL’s commitment to innovation and growth for our customers,” said CEO Cliff Caldwell. “CIL works closely with our diverse and global customers to develop and commercialize exciting, high-value applications for isotopically labeled compounds. As these applications commercialize, our customers rely on CIL’s ability to scale our chemistry quickly and reliably. This land acquisition assures we have the space to continue meeting their expectations and enable these technology advancements.”

    The CIS facility has the world’s largest 13C separation facility, is one of the world’s largest 18O isotope-separation facilities and houses the largest commercial D2O re-enrichment columns in the world.

    Stable isotopes, particularly deuterium, have seen an increase in commercial-scale applications in the last few decades. These applications include pharmaceuticals, semiconductors, flat panel displays, and other high-technology fields. CIL has a three-year supply contract with one Canadian source for D2O, as well as three other sources, and holds an average of an 18-24-month supply in four of CIL locations to ensure the most reliable supply.

    About Cambridge Isotope Laboratories, Inc.

    CIL is the world’s largest manufacturer and global supplier of stable isotopes and stable isotope-labeled compounds used in research, environmental, neonatal, pharmaceutical, medical diagnostic, OLED, and industrial markets. CIL subsidiary ABX in Dresden, Germany, is active in the development and commercialization of radio isotopic-labeled compounds for the diagnosis and treatment of cancers. CIL is an operating business owned by Otsuka Pharmaceutical. The CIL business consists of two facilities in the Boston, Massachusetts, area; a large isotope-enrichment production plant in Xenia, Ohio; CIL China; CIL Canada; ABX in Dresden, Germany; and Eurisotop in Saclay, France. For more information on CIL, visit isotope.com.

    Contact Information

    Crissy Krisko
    crissyk@isotope.com
    1.978.269.1930

    SOURCE: Cambridge Isotope Laboratories, Inc.

    View the original press release on newswire.com.

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

    Related Posts

    Freezz Italia Awarded ESA Contract for IRIS(2) Low-LEO Pre-Operational and De-Risk Activities

    November 17, 2026

    Securitas Healthcare Introduces a New Era of RTLS Built for the Future of Healthcare Operations

    November 10, 2026

    ARC Names UptimeAI Leader in 2026 MarketMap for Industrial Copilots – Plant Operations

    November 2, 2026
    Latest News

    Prabowo says DEFA can unlock $2 trillion ASEAN digital economy

    Business November 18, 2026

    – Indonesian President Prabowo Subianto said the ASEAN Digital Economy Framework Agreement (DEFA) could unlock a regional digital economy worth up to $2 trillion. He made the remarks at the plenary session of the 49th ASEAN Summit at the Philippine

    Tunisia tourism revenues top $2.38 billion by end-October

    November 17, 2026

    Strong bookings push Etihad Calgary flights to daily service

    November 17, 2026

    UAE President and Venezuela’s acting leader discuss closer ties

    November 17, 2026

    UAE and Timor-Leste presidents discuss stronger bilateral ties

    November 16, 2026

    Africa CDC says Congo Ebola outbreak still not under control

    November 16, 2026

    UAE President, Arab League chief discuss regional security

    November 14, 2026

    Morocco secures €434.4 million AfDB loan for reforms

    November 14, 2026
    © 2026 UAE Independent | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.